Dublin, July 06, 2018 (GLOBE NEWSWIRE) -- The "Pediatric Drugs and Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets in US$ Million by the following Therapeutic Class:
- Pediatric Vaccines
- Pediatric Hormones
- Allergy & Respiratory Drugs
- Anti-infective Drugs
- CNS Drugs
- Other Pediatric Drugs
The Pediatric Vaccines market is also analyzed by the following Type:
- Combinations
- Hepatitis
- MMR
- Varicella
- Poliovirus
- Pneumococcal
- Others
The report profiles 90 companies including many key and niche players such as:
- Abbott Laboratories (USA)
- Allergan, Inc. (USA)
- Amgen, Inc. (USA)
- AstraZeneca Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
- Bristol-Myers Squibb Company (USA)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genentech, Inc. (USA)
- GlaxoSmithKline plc. (UK)
- Janssen Biologics B.V. (USA)
- Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
- Merck & Co., Inc. (USA)
- Novartis AG (Switzerland)
- Novo Nordisk A/S (Denmark)
- Pfizer, Inc. (USA)
- Sanofi S.A (France)
- Shionogi Inc. (USA)
- Shire Pharmaceuticals Group Plc. (UK)
Key Topics Covered
1. INDUSTRY OVERVIEW Pediatrics: A Highly Underserved and Undervalued Group Pediatric Drugs Market An Abode of Opportunities The United States: Largest Market for Pediatric Drugs and Vaccines Developing Markets to Witness Faster Growth Antibiotics: Largest Selling Drug Classes Pediatric Vaccines Market On High Growth Trajectory Supply and Demand Dynamics of the Global Vaccine Market UNICEF Addresses BCG Vaccine Supply Shortage Access to Vaccines Index: Aiding Increased Access to Vaccines Recent Advancements/Achievements in the Pediatric Vaccines Space 2. GROWTH DRIVERS AND MARKET TRENDS Pediatric Exclusivity Drives Manufacturers' Interest Pediatric Exclusitivity Granted to Branded Drugs New Product Approvals and Pipeline A Key Growth Propeller Recent Pediatric Drug Approvals: 2015-2017 Pediatric Drug Approvals: 2011-2014 Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017) Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017) Potential for Pediatric Drugs Against Obesity-related Conditions List of Pediatric Drugs for Congestive Heart Failure Treatment Recent Findings to Help Save Children's Lives Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials Modeling & Simulation A Powerful Tool for Pediatric Clinical Study Sponsors Pharmacometrics Approaches Gain Traction Among US and EU Researchers Challenges Associated with Adoption of Pharmacometric Approach Guidelines for Conducting Ethically Correct Clinical Trials Pediatric Drug Market Is Off-label Prescription Justified? Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination Vaccine Refusal by Parents A Growing Trend in the US Market Orphan Drugs for Pediatric Use Gain Popularity List of FDA Approved Orphan Drugs: 2015-2016 List of FDA Designated Orphan Drugs: 2015-2017 Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections Approved Pediatric Antiretroviral Drugs for HIV Treatment Highly Fragmented Growth Hormone Market 3. PEDIATRIC VACCINES MARKET Immunization Coverage Market Share of Leading Pediatric Vaccine Manufacturers Phase III Completed Pediatric Vaccines: 2015-2017 (As of July 2017) Ongoing Phase III Pediatric Vaccines Clinical Trials: 2015- 2017 (As of July 2017) Pediatric Vaccine Types Hemophilus Influenza Type B Vaccine Available Hib and Combination Vaccines Diphtheria/Tetanus/Pertussis Vaccines (DTaP Vaccines) Available DTaP and Combination Vaccines Hepatitis A Vaccine Hepatitis B Vaccine Measles/Mumps/Rubella (MMR) Vaccines Rotavirus Vaccines Polio Vaccines Varicella Virus Vaccine (VAR) Pneumococcal Disease Vaccines Meningococcal Vaccines Combination Vaccines Rising Women Workforce Propels Pediatric Vaccines Growth 4. PEDIATRIC DISEASES OVERVIEW, STATISTICS & TREATMENT Influenza Treatment Urinary Tract Infection (UTI) Prevalence Treatment Mumps Complications Related to Mumps Prevention of Mumps in children Incidence Candidiasis Fifth Disease Molluscum Contagiosum Roseola Tetanus Whooping Cough Allergy and Respiratory Diseases Prevalence Statistics Diphtheria Incidence and Mortality Statistics Upper Respiratory Infection (Common Cold) Diagnosis & Treatment Measles Statistics Asthma Prevalence Central Nervous System Disorders Mental Disorders Attention Deficit Hyperactivity Disorder Prevalence Depression Prevalence Epilepsy Epilepsy Treatment Incidence and Prevalence of Epilepsy in the US Hormonal Disorders Diabetes Mellitus Hypothyroidism Hypothyroidism in Infants and Children Symptoms and Diagnosis Treatment of Hypothyroidism in Children Precocious Puberty Symptoms and Signs Signs of Early Puberty in Girls and Boys Treatment Hypopituitarism Treatment Lymphocytic Thyroiditis Symptoms Treatment Other Diseases Cardiovascular Diseases Cancers 5. LIST OF SELECT FDA APPROVED PEDIATRIC DRUGS 6. PRODUCT INTRODUCTIONS/APPROVALS Actelion Obtains "Epoprostenol Act" Label Extension for Pediatric PAH Patients in Japan FDA Approves Merck's KEYTRUDA (pembrolizumab) Novartis Announces FDAs Acceptance of Company's CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with r/r B-cell ALL Boehringer Ingelheim's Tiotropium Respimat Receives FDA Approval Expansion for Maintenance Treatment of Asthma in Children Sanofi Pasteur terminates a Vaccine Joint-venture with MSD ViiV Healthcare Announces the Changed Opinion of CHMP to Lower the Age and Weight Limit for Tivicay (dolutegravir) in Children and Adolescents Living with HIV in Europe Shire Announces FDA Approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical settings Pfizer Inc. Announces PHASE 3 TRIALs Positive Results of LYRICA (PREGABALIN) Capsules CV and Oral Solution CV for Treating Pediatric Epilepsy Patients Pfizer's Prevenar 13 Receives Approval for Use in Infants and Children in China Simponi Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis Sanofi Pasteur Launches India's first innovative 6-in-1 vaccine Shire launches pediatric indication for immunodeficiency treatment HyQvia in Europe Novo Nordisk's NovoRapid receives positive opinion from CHMP for extended use in European Union for children as young as one year old Boehringer Ingelheim Announces the Ability of Tiotropium Respimat for improving lung function in children aged 6-11 FDA Approves BLINCYTO (blinatumomab) for Use in Pediatric Patients with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia FDA Approves Genentech's Xolair (omalizumab) for Allergic Asthma in Children Novartis Receives EU Approval for Revolade as First-in-class Therapy for Children Aged 1 year and above with Chronic ITP Pandemic Influenza Vaccine Receives Positive Opinion from CHMP GSK's Advair Diskus Exhibits Primary Endpoint in paediatric LABA' Safety Study FDA Accepts Amgen's Supplemental Biologics License Application (sBLA) for The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients with Chronic Severe Plaque Psoriasis Genentech's supplemental Biologics License Application (sBLA) Receives Acceptance from FDA for reviewing Xolair ( omalizumab) Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children Shire Reports Topline Results from Phase 2 Studies in Children with Alagille Syndrome FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients for Immediate Release Sanofi K.K. and Aptalis Pharmaceutical Technologies Launches Allegra Dry Syrup 5% in Japan Sanofi Pasteur Announces Availability of First Doses of Injectable Polio Vaccine ShanIPV(TM) in Near Future for Indian Infants Shire receives CHMP's Positive Opinion in Europe for INTUNIV Novo Nordisk's Levemir Receives Positive Opinion from CHMP for Extended use in Children as Young as one Year Old 7. RECENT INDUSTRY ACTIVITY Johnson & Johnson Acquires Actelion Sanofi Collaborates with MedImmune for development and Commercialization of Monoclonal Antibody for Preventing RSV GSK Intends to Opens a New Global Vaccines R&D Center in Rockville, MD, USA Lupin and Monosol Rx Enters into Licensing Agreement for Developing Multiple Pediatric-Focused Products ICGEB & Sun Pharma Enters into New Exclusive Collaboration to Develop Novel Dengue Vaccine for India & Global Markets Actelion Initiates Phase III Study of Macitentan (Opsumit) for treating Children with PAH Shire and Cincinnati Children's Establishes Rare Disease Research Collaboration 8. FOCUS ON SELECT GLOBAL PLAYERS Abbott Laboratories (USA) Allergan, Inc. (USA) Amgen, Inc. (USA) AstraZeneca Plc. (UK) Boehringer Ingelheim GmbH (Germany) Bristol-Myers Squibb Company (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd (Switzerland) Genentech, Inc. (USA) GlaxoSmithKline plc. (UK) Janssen Biologics B.V. (USA) Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company) Merck & Co., Inc. (USA) Novartis AG (Switzerland) Novo Nordisk A/S (Denmark) Pfizer, Inc. (USA) Sanofi S.A (France) Shionogi Inc. (USA) Shire Pharmaceuticals Group Plc. (UK) 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 90 (including Divisions/Subsidiaries 103)
- The United States (53)
- Canada (3)
- Japan (7)
- Europe (33)
- France (3)
- Germany (1)
- The United Kingdom (6)
- Italy (1)
- Rest of Europe (22)
- Asia-Pacific (Excluding Japan) (7)
For more information about this report visit https://www.researchandmarkets.com/research/f...drugs?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines, Drugs by Therapeutic Area
